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INTRODUCTION 
An abdominal aortic aneurysm (AAA) is a permanent 
dilatation of the infrarenal aorta that can lead to death as a 
result of aortic rupture.
1,2
 AAAs are present in ~5% of 
men and ~1% of women aged over 65 years, but have no 
known medical therapy.
3-7
 Current guidelines comprise 
regular ultrasound imaging until a diameter threshold is 
reached (typically 55 mm), at which point surgical 
intervention is considered.
8
 Patients with symptomatic or 
rapidly expanding AAAs (>10 mm/year) should also be 
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considered for surgical repair. However, currently there 
are no treatments for small AAAs or AAAs in patients 
not suitable for surgical repair.   
Pre-clinical studies employing rodent models of AAA 
have revealed that the peroxisome proliferator activator 
alpha (PPARα) ligand fenofibrate reduces AAA 
development.
9,10
 Data from one study suggests this effect 
may be due to a concomitant reduction of the pro-
inflammatory protein osteopontin (OPN), and reduced 
recruitment of macrophages to the aortic wall.
9
 OPN 
deficiency has been reported to protect against AAA 
formation in a mouse model, and in humans, serum OPN 
levels have been shown to be associated with AAA 
presence and growth.
11,12
 One likely mechanism 
underlying this association is the ability of OPN to 
promote macrophage accumulation within the aorta, 
resulting in the production of a range of proteolytic 
enzymes, such as matrix metalloproteinases (MMPs), 
which are known to cause aortic destruction.
11,13,14
 
Additional studies in rodent models indicate that 
fenofibrate downregulates OPN expression in 
hypertrophied left ventricle cells and dysfunctional renal 
cells, whilst a short course of bezafibrate reduced 
circulating concentrations of OPN by ~23% in diabetic 
patients.
15-17
 The observed ability of fenofibrate to 
downregulate OPN, potentially reducing macrophage 
infiltration and associated release of proteolytic enzymes 
represents a novel approach to limit AAA progression.  
Fenofibrate has other reported effects that suggest it may 
limit aortic destruction. Previous studies have indicated 
that short-term fenofibrate therapy reduces low density 
lipoprotein (LDL) and triglyceride serum concentrations, 
and increases high density lipoprotein (HDL) serum 
concentrations.
18-20
 Low circulating concentrations of 
HDL and high circulating concentrations of triglyceride 
have been associated with AAA in patients.
21-23
 Obesity 
and visceral fat accumulation are risk factors for AAA, 
with analysis suggesting circulating adipokines, in 
particular resistin, may be the cause.
24
 Previous studies 
have reported that fenofibrate downregulates resistin 
production from visceral adipose tissue, thus providing a 
further potential mechanism by which fenofibrate could 
stabilise AAAs.
25,26
 A large body of data implicates 
MMPs in AAA.
21,27
 MMPs, including MMP-9, activate 
pro-inflammatory cytokines and have been shown to 
cleave OPN to a more active form.
28,29
 Data from in vitro 
studies suggests that fenofibrate inhibits MMP-9 
production by vascular cells such as macrophages and 
endothelial cells.
30-32
 Thus the downregulation of MMP-9 
by fenofibrate would be expected to inhibit aortic 
destruction in addition to limiting activation of important 
pro-inflammatory cytokines, such as OPN. 
Kallistatin is a serine proteinase inhibitor, known to be 
expressed in endothelial cells and vascular smooth 
muscle cells.
33
 Overexpression of human kallistatin in 
rodent models has been shown to promote vasodilation.
34
 
More recently, kallistatin has been shown to limit a range 
of mechanisms implicated in AAA pathogenesis, such as 
inflammation, oxidative stress, angiogenesis, and 
hypertension.
35-43
 Thus, identifying treatments that 
upregulate kallistatin may be of benefit in the clinical 
management of AAAs. The effect of fenofibrate on 
serum kallistatin levels in humans has not previously 
been investigated. 
Overall, a large body of data suggests fenofibrate can 
inhibit key pathological mechanisms involved in human 
AAA progression. The aim of the current study is to 
assess the effect of fenofibrate taken daily for 24 weeks 
in participants with small AAAs (35-49 mm) on key 
pathological markers of AAA. The primary aims are to 
determine whether fenofibrate will reduce the serum 
concentrations of OPN, and increase the serum 
concentration of kallistatin. The effect of fenofibrate on 
secondary parameters including serum resistin 
concentration, serum lipids (total cholesterol, 
triglycerides, HDL and LDL), plasma MMP-9 
concentration, other inflammatory markers (such as 
neutrophils, C-reactive protein, cell markers for T cells, B 
cells and neutrophils), and circulating concentrations of 
AAA biomarkers will also be assessed. Finally, AAA 
diameter will be assessed at entry and 6 months by 
ultrasound. 
METHODS 
Study design and participants 
Fenofibrate in the management of AbdoMinal aortic 
anEurysm (FAME)-2 is a multi-centre, prospective, 
randomised, double-blind, placebo-controlled clinical 
trial to assess the effect of 24 weeks of oral therapy with 
145 mg of fenofibrate on circulating pathological markers 
of AAA. The trial will be conducted at four sites in 
Australia: The Royal Brisbane and Women’s Hospital, 
Brisbane; The Townsville Hospital, Townsville; Gosford 
Vascular Services, Gosford and Mackay Base Hospital, 
Mackay. The trial was registered on 18 September 2013 
with the Australian New Zealand Clinical Trials Registry 
(ACTRN 12613001039774). The trial has received 
multicentre ethical approval from The Prince Charles 
Hospital Human Research Ethics Committee 
(HREC/13/QPCH/16) for all four sites. The trial will be 
conducted in agreement with the principles of the 
Declaration of Helsinki. All participants will be informed 
about the purpose of the trial, the risks and benefits, and 
written informed consent will be obtained prior to entry 
by the local study coordinator. Only research personnel 
who are directly involved in the recruitment and data 
collection aspect of the study will have access to patient’s 
personal details. All case report forms (CRF's), source 
documentation and samples will be stored de-identified 
where personal information has been removed and coded 
with a study number.  
The FAME-2 trial will include participants recruited from 
specialist vascular outpatient clinics who provide written 
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informed consent and have an infrarenal AAA measuring 
a maximum orthogonal diameter of 35-49 mm. FAME-2 
will not include individuals with a current indication for 
AAA repair or expectation that this will be revised within 
6 months. Furthermore, participants will only be included 
if they have a high likelihood of treatment compliance 
over 24 weeks. Additional exclusion criteria include 
known contraindications to fenofibrate treatment and 
previous infrarenal abdominal aortic surgery. A full list 
of inclusion and exclusion criteria is given in Table 1. 
Table 1: Patient eligibility criteria. 
Inclusion Criteria 
 Written informed consent 
 Infrarenal AAA measuring a maximal orthogonal 
diameter of 35-49 mm on CTA or ultrasound 
 No current indication for AAA repair according to 
treating physician or expectation that this will be 
revised within 6 months 
 High likelihood of compliance with treatment over 
24 weeks according to treating physician 
Exclusion Criteria 
 Currently taking fenofibrate or related fibrates 
 Contraindication to fenofibrate treatment: 
1. Liver impairment as demonstrated by 
abnormal AST or ALT tests (> 1.5 x ULN) 
2. Renal impairment as demonstrated by an 
elevated serum creatinine level (> 150 µM) 
3. Symptomatic gallbladder disease 
4. Previous reaction to any lipid modifying 
medication 
 Previous infrarenal abdominal aortic surgery 
 Symptomatic, ruptured or mycotic AAA 
 Current participation in another drug trial 
CTA- computed tomographic angiography; AAA- abdominal 
aortic aneurysm; AST- aspartate aminotransferase; ALT- 
alanine transaminase; ULN- upper limit of normal. 
Randomisation and follow-up 
The overall design of the FAME-2 trial is shown in Table 
2. During vascular outpatient clinics, potential 
participants will be pre-screened for suitability and if 
appropriate, informed consent will be obtained. 
Subsequently, potential participants will be assessed 
against the eligibility criteria during the initial visit as in 
Table 1. Individuals will undergo an ultrasound of their 
infrarenal aorta, a medical examination, anthropometric 
assessment (height, weight, waist and hip circumference), 
resting blood pressure, heart rate and ankle-brachial index 
assessments, a quality of life questionnaire, and 
collection of blood samples for measurement of full 
blood count (haemoglobin, white cell count, platelets, 
neutrophils, lymphocytes, monocytes, eosinophils, 
basophils), urea and electrolytes (sodium, potassium, 
creatinine, estimated glomerular filtration rate, albumin, 
total bilirubin, urea, chloride, bicarbonate), liver function 
tests (alanine transaminase, aspartate aminotransferase, 
gamma-glutamyl transpeptidase, lactate dehydrogenase), 
bleeding studies (international normalised ratio, 
prothrombin time, activated partial thromboplastin time, 
fibrinogen), fasting lipids (cholesterol, triglyceride, HDL 
cholesterol, low density lipoprotein cholesterol), fasting 
glucose, C-reactive protein and homocysteine. Serum, 
plasma and whole blood will also be collected for 
assessment of proteins (cytokines) in circulation and 
genetic (DNA and RNA) analysis.  
Blood samples will be processed according to site-
specific standard operating procedures (SOPs) and 
shipped to the study centre in Townsville. Eligible 
participants will be randomised to receive 145 mg 
fenofibrate or placebo, orally once per day, for 24 weeks, 
in a parallel group design. Randomisation to fenofibrate 
or placebo will be stratified by study centre and aortic 
diameter (35-39, 40-44, 45-49 mm). 
Table 2: Summary of assessments. 
 Study time-points (weeks) 
Assessment 0 Visit 1 0 Visit 2 3 Phone call 12 Phone call 24 Visit 3 
Consent X     
Enrolment/Randomisation  X    
Medical examination X    X 
SF-36 questionnaire X    X 
Ultrasound X    X 
Blood test (safety) X  X  X 
Blood collection (study) X  X  X 
Resting ABI X    X 
Physical assessments X    X 
Collection of medication  X    
Return of medication     X 
Drug safety / compliance check   X X X 
Recording of adverse events   X X X 
Physical assessments include: resting blood pressure and heart rate, height, weight, waist and hip measurements. ABI- ankle brachial 
index; SF-36- short form 36. 
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Random allocation sequences will be computer generated 
by a statistician and maintained at the central medication 
centre, ensuring both investigators and participants are 
blinded to drug assignment.  
Trial medication will be allocated and dispensed by the 
local study centre clinical trials pharmacist by telephone 
call. Allocation concealment will be achieved by using 
identical packaging of intervention and placebo. In the 
case of an emergency situation where breaking of the 
group allocation blinding would be required, the clinical 
trial pharmacist at the central medication centre will be 
contacted. To facilitate compliance, participants will be 
provided with the phone number of the local study 
coordinator with instructions to contact in the event of 
possible medication related problems or consideration of 
discontinuation. In this event arrangements will be made 
for the participant to be reviewed by the study physician 
to ascertain if discontinuation is required. Following 
randomisation, participants will receive their allocated 
study medication with instruction regarding dosing 
regimen. Participants will be contacted by telephone calls 
at 3 and 12 weeks after commencement of medication 
and asked about adherence to the study drug regimen as 
well as adverse and clinical events. An additional blood 
test and collection will be performed at 3 weeks, as per 
the initial visit and to assess for safety. All participants, 
including those in whom medication is ceased due to 
adverse events, will be invited to follow-up for the 
duration of the study in the absence of AAA repair. Final 
follow-up will occur at 24 weeks after commencement of 
medication, according to Table 2, at which point the 
participant will discontinue the study medication. 
Compliance with the study medication will be analysed 
by capsule and bottle counting. 
Outcome assessment 
Primary and secondary outcome measures will be 
assessed in blood samples and by AAA imaging at 
baseline and 24 weeks as summarised in Table 3. At 
baseline, 3 and 24 weeks, fasting serum, RNA and 
plasma samples will be obtained, analysed or 
immediately aliquoted and stored at -80°C for later bulk 
analysis. AAA diameter will be measured by ultrasound 
imaging. Reproducible techniques have been established 
to quantify all the primary and secondary outcomes in 
previous studies. RNA will be extracted from total blood 
using previously described methods and stored for future 
microarrays to enable hypothesis generating analyses.
44
 
Outcome assessment will be performed at the study 
centre in Townsville on the tissue and blood samples 
collected. All outcome assessment will be conducted by 
scientists blinded to the treatment allocation of the 
participants.  
Primary outcome assessment 
Serum OPN and kallistatin concentrations will be 
assessed on stored serum using the Quantikine R&D 
Systems ELISA (Minneapolis, USA) according to 
manufacturer’s instructions. The accuracy of this assay in 
measuring serum OPN has previously been assessed. 
Linearity of standards and serum using doubling dilution 
was excellent (R2 0.99), and intra- and inter-assay 
reproducibility were good (concordance correlation 
coefficients 0.997 and 0.929).
12 
Table 3: Summary of primary and secondary 
endpoints. 
Primary endpoint Measurement method 
Serum OPN 
concentration (ng/ml) 
ELISA  
Serum kallistatin 
concentration (ng/ml) 
ELISA 
Secondary endpoint Measurement method 
Serum HDL 
concentration (mM) 
Automated assays 
Plasma MMP-9 (ng/ml) ELISA  
Serum resistin (ng/ml) ELISA  
Other inflammatory 
markers 
ELISA, flow cytometry, 
microarrays and real time 
PCR  
OPN- osteopontin; ELISA- enzyme-linked immunosorbent 
assay; HDL- high-density lipoprotein; MMP-9- Matrix 
metallopeptidase 9; PCR- polymerase chain reaction 
Secondary outcome assessment 
Serum resistin concentration will be assessed using the 
Quantikine R&D Systems ELISA (Minneapolis, USA) 
according to manufacturer’s instructions and expressed as 
nanogram per millilitre. Intra-assay and inter-assay 
coefficients of variation for this assay are between 3% 
and 6% (concordance correlation coefficients ~0.99).
22
 
Serum lipids, including total cholesterol, triglycerides, 
LDL and HDL will be assessed on serum obtained from 
participants who have fasted overnight using automated 
assays (Hitachi 917, Roche Diagnostics GmBH, 
Mannheim, Germany). The inter-assay coefficients of 
variations for these assays have been between 2% and 5% 
in previous studies.
22
 Plasma MMP-9 concentration will 
be measured using Quantikine R&D Systems ELISA, as 
this has previously been shown to be reproducible.
45
 Full 
blood count and C-reactive protein, will be assessed as 
previously described.
46
 Microarrays and real time PCR 
will be used to assess circulating cell markers as 
previously described.
47
  
Ultrasound measurements will be undertaken at entry and 
24 weeks by experienced sonographers within the 
vascular laboratories at each study centre. The 
sonographers will measure the maximum diameters of the 
infrarenal aorta perpendicular to blood flow while the 
participant is in supine and lateral decubitus position. The 
sonographers will measure the diameter two ways; 
between the aortic intima and between the aortic 
adventitia providing an inner-to-inner and outer-to-outer  
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measurement respectively. While the participant is in the 
supine position the sonographer will measure 
anteroposterior and transverse aortic diameters and 
measure anteroposterior aortic diameter only while the 
participant is in the lateral decubitus position. The 
sonographer will also measure the maximum outer-to-
outer anteroposterior common iliac diameters while the 
participant is in the supine position. Static DICOM 
images will be copied by the sonographer, with all 
measurement callipers in place, and sent to the central 
study centre where they will be centrally read by an 
experienced reader at completion of the study. 
Additional outcome measures include change in resting 
brachial blood pressure, resting ankle-brachial index and 
health-related quality of life, as assessed by the Short 
Form-36 (SF-36) questionnaire. Finally, requirement for 
AAA surgery, AAA rupture, all-cause mortality, acute 
cardiovascular events, withdrawal from study medication, 
drug safety and changes in background medication will 
be recorded. 
Study population and power calculation 
The estimated primary outcomes for the placebo group 
are based on assessments performed in human AAA 
blood samples in previous studies.
12,21,22,24
 It is 
hypothesised that administration of 145 mg of fenofibrate 
daily for 24 weeks will result in a 30% increase in serum 
kallistatin and a 30% reduction in serum OPN 
concentrations. These conservative estimates are based 
on previous findings that fenofibrate increases secretion 
of kallistatin by ~300% in aortic VSMC in vitro and 
reduces aortic OPN concentration by ~95% in a mouse 
model of AAA.
9
 They also take into account the reported 
ability of a fibrate to reduce circulating OPN 
concentration by ~23%.
17
 Allowing for a drop-out rate of 
20%, a total of 60 patients per group are required (90% 
power and alpha 0.025, using nQuery Advisor).  
In May 2015 after approximately half the planned 
participants had competed the study, drug compliance 
was analysed by capsule counting and assumed when a 
participant had consumed at least 95% of the planned 
tablets by completion of the study. At that point, 79% of 
participants were deemed compliant. In view of this, the 
planned recruitment target was increased by 20 
participants to minimize the risk of being under powered 
to test the primary hypothesis of the trial.    
Safety 
Outside of its current indication of high serum 
triglyceride, the largest source of available data on 
fenofibrate safety derives from the FIELD study.
19
 In that 
study, 9795 individuals with type 2 diabetes mellitus 
were randomly assigned to receive either fenofibrate or 
placebo for 5 years to assess its effect on cardiovascular 
disease events. Participants were administered a 200 mg 
micronised dose of fenofibrate which is equivalent to the 
145 mg capsule used in FAME-2. The FIELD study 
demonstrated a reduction in total cardiovascular events 
for participants assigned to fenofibrate, as well as a 
significantly reduced rate of progression to albuminuria. 
No significant differences were found between the 
incidence of laboratory abnormalities, minor possible 
drug reactions or possible serious adverse drug reactions 
between the two groups. The median serum creatinine of 
patients taking fenofibrate was 91 versus 80 µM in 
control subjects at the close of study, p <0.001. 
Creatinine was shown to fall by a median of 15 µM in 
661 patients investigated 8 weeks after ceasing 
medication. Conversely, participants assigned to 
fenofibrate were found to have a slowed estimated GFR 
loss over 5 years.
48
 Based on the FIELD study data, it is 
assessed that administration of 145 mg fenofibrate daily 
is likely to be associated with very few serious side 
effects in the FAME-2 study. 
Participant safety will be assessed prior to the 
administration of the medication and at 3 and 24 weeks. 
At the initial visit, a consultation with a physician will 
occur, during which the participant will be informed 
about known side effects including symptoms of 
abdominal/back pain, chest pain and muscle aching. 
Pathology tests consisting of full blood count, fasting 
lipids, glucose, inflammation markers, liver and renal 
function will be performed.  
Physical assessments including blood pressure and heart 
rate will be reviewed by a medical officer along with the 
results of the pathology tests prior to randomisation. At 3 
and 24 weeks, pathology tests as per the initial visit will 
be performed and reviewed by a medical officer. Any 
adverse event will be reported to the coordinating centre 
and carefully monitored throughout the study. Serious 
adverse events (SAEs) will be defined as death, 
medically important, requirement for in-patient hospital 
treatment and persistent of significant disability. All 
SAEs will be reported by the site principle investigator to 
HREC and reviewed by the chief principle investigator, 
where a decision regarding withdrawal of trial medication 
will be made. Where a decision to withdraw trial 
medication is made, participants will be encouraged to 
remain on the study protocol.  
Data management and analysis 
The data management committee will comprise the chief 
investigators at each of the sites involved. Trial 
documentation including protocols, SOPs and CRFs will 
be shared electronically with participating study centres. 
Protocol amendments will be submitted to The Prince 
Charles Hospital HREC and local site Research 
Governance offices, and disseminated to the relevant 
parties at each study site. Data recorded on printed CRFs 
will be scanned to the study centre in Townsville where it 
will be entered centrally and examined for data quality. 
This will allow confirmation of entry criteria, and 
collection of set entry and outcome data. Examples of 
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important baseline data which will be collected include 
age, gender, risk factors, concurrent medications and 
morphology of the AAA assessed from ultrasound. 
Definitions and accurate methods to quantify these data 
have been developed in previous studies.
22,24
 At 
completion of the trial the database will be checked for 
errors and data confirmed with source documentation 
where required. Analysis of primary and secondary 
endpoints will be based on intention to treat at the time of 
randomisation.  
All participants who meet the eligibility criteria, provide 
written informed consent and are enrolled in the study 
will be included in the primary analysis, regardless of 
adherence to medication allocation. Data will be analysed 
with appropriate non-parametric or parametric tests 
depending on data distribution and, if appropriate, 
multivariate tests such as logistic regression will be used 
to adjust for confounding factors. Data will be published 
in a peer-reviewed journal with copies of the paper 
available to participants if required. 
DISCUSSION 
There is no known effective medical therapy to limit 
AAA growth, and to date large randomised controlled 
trials have failed to report the benefit of any tested 
agent.
49-52
 Furthermore, early elective endovascular repair 
or open surgery for patients with AAAs measuring 40-54 
mm has not been found to improve mortality rates.
53-56
 
Identification of a novel therapy to limit AAA expansion 
would represent a significant breakthrough in the clinical 
management of this disease. In the current study the 
effect of a promising new medical therapy will be 
assessed.  
The study has been specifically designed to determine 
whether findings in rodent models can be confirmed in 
patients, and will enable the determination of whether: a) 
fenofibrate can rapidly inhibit key pathological 
mechanisms of AAA progression; b) the efficacy of 
fenofibrate in limiting AAA inflammation can be 
monitored in blood samples. Thus, FAME-2 has the 
potential of identifying a medication which can limit key 
pathological mechanisms in AAAs and may offer a 
means to monitor efficacy of the drug via a simple blood 
test. If findings from this pilot study are positive, larger 
trials will be needed to examine the benefit of fenofibrate 
over longer follow-up in a larger cohort of patients. 
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